Application progress of sFlt-1/PLGF ratio in preeclampsia
Shan Lei, Zhou Tao, Qiu Juanjuan, et al
(1. Department of Obstetrics, Quzhou Hospital Affiliated to Wenzhou Medical University, Zhejiang, Quzhou 324000, China; 2. Department of Obstetrics, the Affiliated Suzhou Hospital of Nanjing Medical University, Jiangsu, Suzhou 215000, China)
Abstract: 【Abstract】Preeclampsia is one of the most common causes of adverse maternal and neonatal outcomes,even death. The ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PLGF) as a direct indicator of the dysregulation within placental syncytiotrophoblast cells. This ratio is poised to emerge as a pivotal biomarker for the prediction, auxiliary diagnosis, and prognosis of preeclampsia. This article delineates the pathophysiological role of the sFlt-1/PLGF ratio in the etiology and progression of preeclampsia. Furthermore, it offers a comprehensive summary of the clinical research advancements concerning the application of the sFlt-1/PLGF ratio in diagnosing, predicting, and treatment of preeclampsia.
Neonatal Pediatrics Branch of Chinese Medical Doctor Association, Neonatal Health Professional Committee of China Maternal and Child Health Association, Editorial Board of the Journal of Developmental Medicine (Electronic Version). Expert consensus on the use of placental transfusion in neonates with special obstetric conditions[J]. Journal of Developmental Medicine(Electronic Version), 2021, 9(5): 321
-328
.